North America Tissue Diagnostics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America Tissue Diagnostics Market Overview

Tissue diagnostics continues to evolve through innovations that improve diagnostic accuracy and support better clinical outcomes across a broad range of diseases. The market is poised to grow at a CAGR of 9.80% during the forecast period of 2026-2035. It is driven by advanced healthcare infrastructure, increasing demand for precision medicine, growing prevalence of chronic diseases, and widespread adoption of digital pathology and molecular diagnostics.

North America Tissue Diagnostics Market Growth Analysis and Key Influencers

North America Tissue Diagnostics Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

North America Tissue Diagnostics Market Growth Drivers

AI-Driven Digital Pathology Innovations to Accelerate the Market Value

The increasing adoption of artificial intelligence (AI)-enabled digital pathology solutions is accelerating the market by improving diagnostic accuracy, streamlining laboratory workflows, and supporting precision medicine. Advanced AI tools enable pathologists to identify complex tissue abnormalities more efficiently, leading to faster and more reliable diagnoses. For instance, in November 2024, PathAI ranked 420th after achieving 260% revenue growth from 2020 to 2023. In addition, Quest Diagnostics announced agreements in 2024 to license PathAI's AISight™ digital pathology image management system for use in its U.S. pathology laboratories and customer sites. These developments highlight increasing adoption of AI-powered pathology solutions and the integration of digital pathology into clinical laboratory workflows, supporting the continued expansion of the tissue diagnostics market.

North America Tissue Diagnostics Market Restraints

Shortage of Skilled Pathologists Limits Diagnostic Efficiency in the Market

The limited availability of skilled pathologists and laboratory professionals continues to challenge the market by slowing diagnostic workflows and increasing pressure on healthcare systems. Rising testing volumes and the growing complexity of tissue-based diagnostics require specialized expertise for accurate interpretation. In addition, variations in laboratory infrastructure and digital pathology adoption can further affect workflow efficiency and consistency, limiting the ability of healthcare providers to meet the increasing demand for timely and precise tissue diagnostics.

North America Tissue Diagnostics Market Opportunities

Expanding AI-Enabled Precision Oncology Creates New Growth Potential for the Market

The increasing integration of artificial intelligence into digital pathology platforms is creating significant opportunities by enhancing cancer diagnosis, supporting precision medicine, and enabling personalized treatment decisions. AI-driven algorithms improve tissue analysis while helping clinicians identify disease characteristics with greater accuracy and efficiency. For instance, in September 2024, Roche expanded its digital pathology open environment by integrating more than 20 AI algorithms from eight collaborators to strengthen cancer diagnostics and personalized healthcare. Roche stated that the integration was intended to support pathologists and scientists in cancer research and diagnosis and to facilitate precision medicine and targeted treatment decisions. Such advancements are expected to accelerate innovation and support the long-term expansion of the market.

North America Tissue Diagnostics Market Trends

The market is witnessing several trends, including AI-powered digital pathology, integrated diagnostic workflows, and enterprise digital solutions.

Growing Adoption of Integrated Digital Pathology Ecosystems Is Likely to Strengthen the Market Landscape

The increasing adoption of integrated digital pathology ecosystems is transforming diagnostic workflows by improving collaboration, image management, and clinical decision-making across pathology laboratories. For instance, in March 2026, Leica Biosystems and Indica Labs launched the Aperio HALO AP DX software for use with the Aperio GT 450 DX scanner in the United States, providing a complete clinical digital pathology ecosystem for routine diagnostics. This trend is expected to enhance workflow efficiency and support the sustained growth of the market.

North America Tissue Diagnostics Market Share

Immunohistochemistry Is Expected to Maintain Its Leading Position in the Market by Technology

The market is segmented by technology into immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, special staining, and others. Among these, immunohistochemistry (IHC) is expected to lead due to its widespread use in cancer diagnosis, biomarker identification, companion diagnostics, and treatment selection. For instance, in July 2025, Roche Tissue Diagnostics highlighted 40 years of innovation in pathology, emphasizing the advancement of automated immunohistochemistry and companion diagnostics. Roche reported that its pathology business supports 4.3 million patients tested annually through three companion diagnostic tests and 41 million patients globally each year, while its full companion diagnostic portfolio enables access to 19 personalized therapies. These developments are expected to strengthen the adoption of immunohistochemistry and reinforce its leadership in the market.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America Tissue Diagnostics Market Analysis by Region

The regions included in the report are the United States and Canada. Among these, the United States is expected to lead due to its high cancer burden, advanced diagnostic infrastructure, and strong adoption of innovative tissue diagnostic technologies. According to the Centers for Disease Control and Prevention (CDC), 288,494 new breast cancer cases were reported among females in the United States in 2023, while 43,402 breast cancer-related deaths were recorded in 2024. The substantial burden of breast cancer supports continued demand for accurate and early cancer diagnosis in the United States.

Leading Players in the North America Tissue Diagnostics Market

North America Tissue Diagnostics Market Segmentation

Key Questions Answered in the North America Tissue Diagnostics Market Report

• What was the North America tissue diagnostics market value in 2025?
• What is the North America tissue diagnostics market forecast outlook for 2026-2035?
• What are the major factors aiding the North America tissue diagnostics market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major North America tissue diagnostics market trends?
• Which product and services is expected to dominate the market segment?
• Which technology is projected to lead the market segment?
• Which application is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the North America tissue diagnostics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed using a comprehensive mixed-methods research approach combining qualitative insights and quantitative market analysis:

• Primary Research: In-depth interviews with 30+ pathologists, oncologists, laboratory directors, diagnostic laboratory managers, digital pathology specialists, and procurement professionals across the United States and Canada, including key opinion leaders (KOLs) from leading hospitals, cancer centers, research institutes, and pathology laboratories.
• Secondary Research: Peer-reviewed publications from The American Journal of Surgical Pathology, Modern Pathology, The Journal of Molecular Diagnostics, and The Lancet Oncology; regulatory data from the FDA and Health Canada; epidemiological statistics from the CDC, NIH, WHO, and GLOBOCAN; clinical trial data from ClinicalTrials.gov; patent databases; company annual reports, investor presentations, product portfolios, press releases, SEC filings, and official corporate websites.
• Validation: All market estimates are triangulated using top-down and bottom-up market modeling techniques and validated through iterative expert review and feedback.